Tri-functional T cell receptor antigen coupler (Tri-TAC): a novel method to direct T cells against tumors by unknown
POSTER PRESENTATION Open Access
Tri-functional T cell receptor antigen coupler
(Tri-TAC): a novel method to direct T cells
against tumors
Christopher Helsen, Ben Li*, Galina Denisova, Jonathan L Bramson
From Society for Immunotherapy of Cancer 29th Annual Meeting
National Harbor, MD, USA. 6-9 November 2014
Engineering T cells with chimeric antigen receptors
(CARs) is proving to be an effective method for directing
T cells to attack tumors in an MHC-independent manner.
Current generation CARs aim to recapitulate T cell signal-
ing by incorporating modular functional components of
the TCR and costimulatory molecules. Development of
next generation CARs has relied upon trial and error eva-
luation of signaling domains. We sought to develop an
alternate method to re-direct the T cell receptor which
does not rely upon the incorporation of signaling domains
into the chimeric receptor. To this end, we developed a
tri-functional molecule which is membrane-anchored and
redirects the TCR in the presence of tumor antigen. We
also included components of the CD4 co-receptor to pro-
vide requisite Lck signaling upon ligation of the tumor
antigen. Our prototype receptor was directed against the
HER-2 proto-oncogene. We have determined that engi-
neering peripheral blood T cells with this novel receptor
(termed a Tri-TAC) engenders tumor-antigen specific
activation of numerous T cell functions, including cyto-
kine production, degranulation and cytolysis - equivalent
to, if not greater than, a 2nd generation CAR bearing the
CD28 and CD3zeta signaling domains. Future iterations of
the engineered T cells will include chimeric costimulatory
receptors to enhance T cell functionality and reduce off
target toxicity. This research was supported by the Cana-
dian Institutes of Health Research and the Terry Fox
Foundation.
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